Natco Pharma share news, announcements and annual reports
NSE: NATCOPHARMBSE: 524816Pharmaceuticals & BiotechnologySmall Cap
Natco Pharma Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, Dec 1995 on NSE
Last close ₹782.40down ₹5.15 (0.65%)BSE ₹782.50
Share price at the NSE close on 30 Oct 2026. Previous close ₹787.55.
30 Oct: open ₹792.05, high ₹800.90, low ₹779.50
52-week range of traded prices to 30 Oct 2026
₹773.60Low, 22 Oct 2026₹1,226.80High, 12 May 2026
- Next results date: the board meets on 13 Nov 2026 to consider: financial results and dividend. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹15,348 Cr380th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 13.41
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.58%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 8.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.08
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 3,21,54744.0% delivered
Natco Pharma share news and announcements
1,035 announcements, routine notices left out, newest first. Page 18 of 21.
Feb 2011
14 Feb · Dividend
Board of Directors of the Company at its meeting held on February 14, 2011 has recommended payment of an interim dividend of Rs.2/- per equity share of Rs.10/- each for the year 2010-2011 and the pay-by date of the same is March 10, 2011.2 Feb · Board meeting
To consider among other things, the unaudited financial Results for the quarter ended December 31, 2010, and to consider Interim Dividend, if any, for the financial year 2010-11 and related matters etc.
Jan 2011
14 Jan · Business
Dec 2010
Nov 2010
26 Nov · Limited Review Report
Auditors have conducted the limited review for the un-audited financial results for the quarter ended September 30,2010. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.15 Nov · Board meeting
Board of Directors of the Company, at their meeting held on November 15, 2010, considered the following: (1) Compensation Committee granted 6,00,000 options of Rs.10/- each to the employees under Employee Stock Option Scheme NATSOP2010; (2) The Company is planning to raise funds to the tune of Rs.100 crores through appropriate capital offering. For seeking shareholders approval Board decided to convene Extra-ordinary General Meeting (EGM) of the Company to be held on December 15, 2010.2 Nov · Board meeting
To consider among other things, the unaudited financial Results for the quarter ended September 30, 2010 and related matters etc.
Oct 2010
Sep 2010
6 Sep · Meeting
Register of Members and Share Transfer Books of the Company will remain closed from September 27, 2010 to September 30, 2010 (both days inclusive) for the purpose of Annual General Meeting. The Annual General Meeting of the Company will be held on September 30, 2010.
Aug 2010
19 Aug · Limited Review Report
Auditors have conducted the limited review for the un-audited financial results for the quarter ended June 30,2010. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.16 Aug · Audit Qualifications/Comments
16 Aug · Audit Qualifications/Comments
3 Aug · Board meeting
Board of Directors at their meeting held on July 31, 2010 have taken on record the following : (1) To convene Annual General Meeting (AGM) of the Company to be held on September 30, 2010; (2) Issue of shares to the employees of the Company under Employee Stock Option Scheme (ESOS).
Jul 2010
21 Jul · Board meeting
To consider among other things, the unaudited financial Results for the quarter ended June 30, 2010, convening of Annual General Meeting and related matters etc.
Jun 2010
May 2010
26 May · Board meeting
To consider among other things, consideration of audited financial results for the year ended March 31, 2010 and related matters.4 May · Results
Company will be considering the Audited Results for the quarter ending 31st March, 2010 instead of un-audited Results and will be announced on or before 30th May, 2010.
Apr 2010
20 Apr · Board meeting
Board of Directors of the Company had its meeting held on April 19, 2010 resolved to convene an Extraordinary General Meeting of the members of the Company to be held on May 18, 2010 for consideration of Increase in Authorised Share Capital, Amendment to the Memorandum and Articles of Association and for filling the casual vacancy in the office of the Auditor.7 Apr · Press Note
Press note dated April 07, 2010, titled "NATCO launches BENDIT". A copy of the press note shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2010
27 Jan · Business
Press release dated January 27, 2010, which is as follows: "Hyderabad based NATCO Pharma Limited had recommended a payment of Rs.2 per equity share as an interim dividend for the financial year 2009-10. The Board of Directors, which met at Hyderabad today noted, that the company has recorded a 11% growth in revenues on a year-on-year on basis (at Rs.83 Crores in the third quarter of the current fiscal as against Rs.75 Crores in the last year). The net profit, after tax, on a stand-alone basis has also gone up by 7% on a year-on-year basis (from Rs.1128 lakhs to Rs.1209 lakhs) in the third quarter of the current year. On a consolidated basis, the cumulative earnings up to end of December, 2009 amounted to Rs.349 Crores (as against Rs.331 Crores last year), while the cumulative profit after tax stood at Rs.3368 lakhs (as against Rs.3271 lakhs last year)".27 Jan · Corporate action
Record date for the purpose of payment of interim dividend, declared at the board meeting held on January 27, 2010, is fixed as February 08, 2010.27 Jan · Dividend
Board of Directors of the Company at their meeting held on January 27, 2010 recommended payment of an interim dividend of Rs.2/- per share of Rs.10/- each for the year 2009-2010.13 Jan · Board meeting
Board Meeting is convened to consider among other things, consideration of declaration of Interim Dividend, if any, for the Financial Year 2009-2010, the un-audited financial results (Provisional) for the quarter ended December 31, 2009 and related matters.11 Jan · Press Note
Press release dated January 09, 2010 with respect to the Government of India has stayed the suspension of its Albupax manufacturing (product) license. Albupax is a nanotechnology based drug and is the first generic version of the international brand - Abraxane of Abraxis Bioscience Inc., USA. A copy of the press note shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Nov 2009
27 Nov · Press Note
Press note dated November 26, 2009, titled "Glatiramer Acetate : TEVA's Citizen Petition A Ploy To Delay Generic Competition". A copy of the press note shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2009
29 Oct · Press Note
Press note dated October 29, 2009, titled "NATCO records increase in revenues, profits". A copy of the note release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 Oct · Updates
Clarifying note issued by the Company titled " Natco's note on anti-cancer drug Albupax". A copy of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 Oct · Board meeting
To consider among other things, the unaudited financial Results for the quarter ended September 30, 2009.5 Oct · Change in Nominee Director
EXIM Bank of India has withdrawn Shri Mukul Sarkar and appointed Shri. C.P. Ravindranath as its Nominee Director on the Board
Sep 2009
29 Sep · Meeting
Members of the Company at their Annual General Meeting for the financial year 2008-09 held on September 29, 2009 have passed various resolution. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Sep · Press Note
Press note dated September 18, 2009 titled "NATCO launches Swine Flu medicine". A copy of the press note shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Sep · Press Note
Press note dated September 14, 2009 titled "NATCO's partner - Mylan's - ANDA accepted for review of Glatiramer Acetate". A copy of the press note shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Sep · Meeting
Annual General Meeting of the Company for the year 2008-2009 will be held on September 29, 2009. Further, the Register of Members and Transfer books of the Company will remain closed from September 22, 2009 to September 29, 2009 (both days inclusive) for the purpose of Annual General Meeting of the Company.
Jul 2009
30 Jul · Board meeting
Board of Directors have taken on record the following at their meeting held on July 30, 2009 : 1) Dr. A.K.S. Bhujanga Rao inducted as an Additional Director of the Board and designated him as President (R&D and Technical). 2) Board authorised Chairman and Managing Director of the Company to fix up the date of Annual General Meeting, Book Closure dates and venue etc.20 Jul · Board meeting
To consider among other things, the Unaudited financial Results for the quarter ended June 30, 2009 and convening of Annual General Meeting and related matters etc.
Jun 2009
30 Jun · Board meeting
Board of Directors of the Company at their meeting held on June 30, 2009 considered and approved the Audited Results for the quarter ended March, 2009. Further:- 1)Mrs. Durgadevi Nannapaneni, Whole Time Director of the Company resigned as a Director and to the position of the Whole Time Director w.e.f. July 1, 2009 due to her personal reasons. 2) Company allotted 1,07,125 shares under ESOP 2004 out of which 12,500 shares were allotted to Dr. Jasti S. Rao, an independent Non-promoter Director and 2,500 shares to Mr. P.Bhaskara Narayana, Director & Chief Financial Officer.